دورية أكاديمية
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer
| العنوان: | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer |
|---|---|
| المؤلفون: | Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, Charles Kent |
| المساهمون: | Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andre, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, Charles Kent |
| سنة النشر: | 2020 |
| المجموعة: | IRIS Università degli Studi di Napoli Federico II |
| الوصف: | Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000514157200008; volume:26; issue:4; firstpage:821; lastpage:827; numberofpages:7; journal:CLINICAL CANCER RESEARCH; http://hdl.handle.net/11588/773784Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85078302508 |
| DOI: | 10.1158/1078-0432.CCR-19-0851 |
| الإتاحة: | https://doi.org/10.1158/1078-0432.CCR-19-0851Test http://hdl.handle.net/11588/773784Test |
| رقم الانضمام: | edsbas.7FE37542 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/1078-0432.CCR-19-0851 |
|---|